Trial Profile

Global Phase 3 registrational study assessing BV100

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 09 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifabutin (Primary)
Indications Bacterial infections; Ventilator associated pneumonia
Focus Registrational; Therapeutic Use
Sponsors BioVersys

Most Recent Events

02 Jul 2025 According to a BioVersys AG media release, the company remains on track to initiate the Phase 3 trial for our most advanced asset BV100 later this year .
16 Oct 2024 According to a BioVersys AG media release, Company expects to initiate trial in the second half of 2025.
17 Sep 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com